Skip to main content
Log in

New targets may lead to novel classes of anti-obesity drugs

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

Although a number of appetite suppressants are now in clinical trials, the search for new anti-obesity drug targets continues. Recent advances in basic science have unveiled 2 new receptors that may prove to have potential in this field. They are the neuropeptide Y (NPY)-5 receptor and the peroxisome proliferator activated receptor (PPAR)-γ. These possible new approaches to the treatment of obesity were discussed at the 3rd IBC USA conference on ‘Obesity - Advances in Understanding and Treatment’ [ San Diego, US; September 1996 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Higgins, G. New targets may lead to novel classes of anti-obesity drugs. Inpharma Wkly. 1062, 7–8 (1996). https://doi.org/10.2165/00128413-199610620-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199610620-00015

Keywords

Navigation